Estrogens
(ovarian synthesis, metabolism and mechanisms of action)

Estrogens constitute the principal steroid system of the ovary and represent the endocrine signal that links follicular growth, selection of the dominant follicle, gonadotropic feedback and the function of reproductive and non reproductive target tissues. From a biological perspective, the three reference molecules are estradiol (E2), estrone (E1) and estriol (E3), but in women of reproductive age the physiological focus is estradiol, which predominates because of its receptor potency, cyclic relevance and role in regulating the hypothalamic pituitary ovarian axis. The ovary does not produce estrogens as isolated entities, but as the result of cellular and enzymatic cooperation that converts androgen precursors into a hormonal signal that is finely modulated over time.

Estrogen physiology is one of the clearest examples of integration among steroidogenesis, follicular biology and molecular regulation of endocrine action. Ovarian synthesis depends on cholesterol availability, functional compartmentalization between theca and granulosa cells, aromatase activity and modulation by FSH and LH. Systemic and tissue metabolism instead depends on interconversions between estradiol and estrone, hydroxylation and conjugation reactions and the ability of peripheral tissues to produce or locally inactivate the signal. Biological action occurs mainly through estrogen receptors and transcriptional regulation, but also includes rapid non genomic pathways that expand the temporal and functional spectrum of estrogen effects. This page follows the estrogen system along its entire functional chain, from ovarian biosynthesis to compartment specific regulation of its actions in different tissues.

The ovarian estrogen system is based on the enzymatic conversion of androgen precursors. The ovary does not synthesize estradiol through a separate autonomous pathway, but through the conversion of androstenedione and testosterone generated in the theca and subsequently aromatized within granulosa cells. This organization gives the estrogen signal an intrinsically integrated nature, because the amount of estrogen produced depends not only on the availability of the steroidogenic substrate, but also on the degree of follicular maturation, sensitivity to gonadotropins and the enzymatic profile of the different follicular cell populations.

Among the different estrogen molecules, estradiol is the main effector in women of reproductive age. Estrone has lower biological potency, but represents an important interconvertible metabolite and a relevant component of estrogen signaling in certain peripheral and postmenopausal settings. Estriol, by contrast, has a quantitatively and functionally smaller role in ordinary ovarian physiology and becomes particularly important mainly in the fetal placental context. This hierarchy clarifies that the “estrogen signal” does not simply correspond to the presence of estrogens in the blood, but to the availability of the most active form within target tissues and to the capacity of those tissues to convert, use or inactivate it.

From an endocrinological perspective, estrogen action is therefore compartment specific. The circulation transports hormones bound to plasma proteins and maintains continuity of the signal, but the final effect depends on how much hormone reaches the tissues, how it is locally interconverted and how it interacts with receptors, transcriptional coregulators and other signaling systems. This principle explains why two conditions with apparently similar plasma concentrations do not necessarily produce the same intensity of biological response and why the role of estrogens cannot be interpreted solely on the basis of an isolated serum value.

Three principles explain why estrogen signaling is dynamic over time but selective across tissues:

• androgen precursors produced in the theca and converted into estrogens within granulosa cells;
• central role of estradiol as the principal biological effector in women of reproductive age;
• local modulation of the signal through tissue metabolism, interconversions and receptor regulation.

This conceptual architecture makes it necessary to begin with ovarian steroidogenesis. Only by understanding how the follicle generates androgen precursors, how it transfers them between its cellular compartments and how it converts them into estrogens is it possible to interpret the cyclic physiology of estradiol and its systemic endocrine significance.

Estrogen synthesis in the ovary begins with cholesterol, which is the common precursor of all steroid hormones. Transfer of cholesterol to the inner mitochondrial membrane, a step regulated by the StAR protein, initiates steroidogenesis through the formation of pregnenolone. From this point onward, the biosynthetic pathway differs among the various follicular compartments according to their cellular enzymatic profile, creating a division of labor that is essential for estrogen production.

Cells of the theca interna, predominantly stimulated by LH, express the enzymes required to generate androgens, particularly androstenedione and testosterone. These cells possess robust steroidogenic capacity, but they are not the final site of estrogen synthesis because aromatase activity is limited or absent. The androgens produced in the theca therefore diffuse toward the granulosa compartment, where they are used as substrates for estrogen synthesis.

Granulosa cells, particularly in growing follicles, respond to FSH by increasing expression of aromatase (CYP19A1), the key enzyme that converts androstenedione into estrone and testosterone into estradiol. Estrone can in turn be converted into estradiol by enzymes of the 17β hydroxysteroid dehydrogenase family. In this way, granulosa cells not only convert androgen substrates into estrogens, but also modulate the quality of the final signal by favoring production of the most biologically active form.

The model of theca granulosa cooperation is not merely a histological description, but a decisive physiological principle. LH ensures the availability of androgen substrate, FSH enables estrogen conversion and follicular maturation progressively coordinates the two processes. Consequently, the capacity to produce estradiol increases with follicular growth and functional expansion of the granulosa layer, making estrogen secretion a direct indicator of the endocrine competence of the dominant follicle.

Estrogen biosynthesis is also influenced by intraovarian paracrine and autocrine signals. Growth factors, ovarian peptides, signals derived from the oocyte and interactions with the stromal matrix modulate enzyme expression and sensitivity to gonadotropins. This clarifies that estrogen steroidogenesis depends not only on the central axis, but also on the biological quality of the follicular microenvironment. Estradiol production therefore reflects not only hormonal stimulation, but also the organizational state of the follicle as a dynamic endocrine unit.

As progression toward the preovulatory phase occurs, the dominant follicle acquires marked aromatase efficiency and produces increasing amounts of estradiol. This increase is not merely an end product of follicular growth, but an active signal that feeds back on the axis, the endometrial mucosa, cervical mucus and other target tissues, preparing the body for ovulation and the subsequent luteal phase.

Estrogen secretion varies continuously during the ovarian cycle and reflects the sequence of follicular events. During the early follicular phase, estradiol levels are relatively low because early antral follicles, although metabolically active, have not yet developed full steroidogenic capacity. As follicular selection progresses, the increase in granulosa cell mass and aromatase activity leads to a progressive rise in plasma estradiol.

This estrogen increase has a dual significance. On the one hand, it indicates that the dominant follicle is acquiring endocrine and ovulatory maturity. On the other hand, it modifies feedback on the hypothalamic pituitary axis. During most of the cycle, estradiol exerts predominantly negative feedback on gonadotropins, but when it reaches high and sustained concentrations for a critical interval, it contributes to activation of the positive feedback that culminates in the LH surge. The preovulatory estrogen peak is therefore not simply a quantitative increase, but a functional threshold that changes the regulatory logic of the axis.

After ovulation, the corpus luteum continues to secrete estrogens together with progesterone. During this phase, the estrogen signal assumes an integrative role, contributing to stabilization of the endometrium, modulation of genital secretions and maintenance of central feedback within a regulatory setting that differs from the follicular phase. Although progesterone becomes the dominant hormone, the estrogen component remains physiologically relevant and contributes to defining luteal function.

Regression of the corpus luteum, in the absence of pregnancy, causes a reduction in progesterone and estrogen production. The decline in estrogen, together with progesterone withdrawal, contributes to the endometrial changes that culminate in menstruation and removes inhibition of the axis, allowing initiation of a new cycle. Estrogens must therefore be understood as signals that not only accompany the cycle, but also organize its fundamental biological transitions.

This cyclic nature profoundly distinguishes ovarian estrogen physiology from that of other, more stable endocrine systems. Serum concentration does not represent a fixed “normal” value, but a temporal variable whose significance depends on the phase of the cycle, the quality of follicular growth and interaction with the other hormones of the reproductive axis.

In the blood, estrogens circulate largely bound to plasma proteins, particularly SHBG and albumin. Protein binding is not merely a passive phenomenon, but an essential component of the physiology of the system because it stabilizes the hormone in the circulation, limits acute fluctuations and creates a reservoir that contributes to continuity of the signal. The free fraction is quantitatively small but biologically decisive, because it is immediately available for passage into tissues and interaction with cellular receptors.

SHBG has particular endocrinological relevance because it modulates the bioavailability of sex steroids. Variations in its concentration can alter the free fraction of estradiol even when total levels are relatively similar. This explains why interpretation of estrogen signaling cannot stop at measurement of total hormone and must take into account the metabolic, hepatic and hormonal context that influences binding proteins.

From a physiological perspective, plasma transport allows estrogens to be efficiently distributed to very different tissues. The genital tract, bone, liver, cardiovascular system, skin and central nervous system receive the signal within a dynamic equilibrium between the bound and free fractions. Plasma binding attenuates immediate variability, but does not by itself determine the intensity of action, which also depends on local metabolism and receptor expression in the different tissues.

Transport properties also contribute to the biological pharmacokinetics of the different estrogen molecules. Estradiol, estrone and their metabolites do not have identical affinity for binding proteins or identical metabolic behavior, and this affects signal persistence, tissue distribution and the possibility of peripheral interconversion. For this reason as well, estrogen physiology cannot be reduced to a simple curve of ovarian secretion.

Plasma transport, however, represents only one level of regulation. To understand how the signal is actually used by tissues, it is necessary to consider peripheral metabolism, meaning the set of transformations that can activate, attenuate or eliminate estrogen action locally and systemically.

Estrogen metabolism is a central regulatory process because it determines both the duration of the signal and its biological intensity in different tissues. One of the most important reactions is the interconversion between estradiol and estrone, mediated by enzymes of the 17β hydroxysteroid dehydrogenase family. This conversion is physiologically relevant because it enables transition from a form with greater receptor potency to a less potent form and vice versa, modulating the signal according to the tissue context.

In addition to interconversions, estrogens undergo hydroxylation reactions, which occur mainly in the liver but also in other tissues. These transformations generate metabolites with differing biological activity and prepare the hormone for subsequent phases of conjugation. Sulfation and glucuronidation increase the water solubility of metabolites and facilitate their biliary and urinary elimination, contributing to systemic inactivation of the signal.

Estrogen metabolism is not, however, merely a clearance system. In numerous peripheral tissues, particularly adipose tissue, transformations can occur that contribute to local production of estrogens from androgen precursors. This aspect becomes increasingly important when ovarian production declines, as in the postmenopausal period, but it is also physiologically relevant during reproductive age because it demonstrates that the estrogen system does not entirely coincide with gonadal secretion.

From an endocrine perspective, this means that the estrogen signal results from the sum of ovarian production, peripheral conversions and metabolic inactivation. A tissue may be exposed to different amounts of estradiol or estrone not only according to circulating levels, but also according to its own capacity to locally convert and metabolize steroids. This property makes estrogen physiology strongly dependent on the biological context of each individual tissue.

Metabolism also integrates with enterohepatic circulation, which contributes to persistence of the steroid signal and its systemic stability. Although ovarian synthesis remains the main driver of cyclic physiology, the duration and quality of estrogen exposure depend substantially on these accessory metabolic circuits, which connect the reproductive system to hepatic, intestinal and general metabolic function.

The classical action of estrogens is mediated by estrogen receptors, members of the nuclear receptor superfamily. The two principal isoforms, ERα and ERβ, have different tissue distributions and contribute to the specificity of biological effects. After ligand binding, the receptors undergo a conformational change, dimerize and interact with specific regulatory DNA sequences or with other transcription factors, thereby modulating expression of target genes.

Depending on the molecular context, the receptor complex can recruit coactivators or corepressors, influencing chromatin accessibility, histone acetylation and the activity of the transcriptional machinery. Consequently, the same concentration of estradiol does not necessarily produce the same response in all tissues, because the final effect depends on the composition of the receptor complex, receptor density and the epigenetic and functional state of the target cell.

The genomic effects of estrogens are broad and involve proliferation and differentiation of the genital epithelium, endometrial growth and receptivity, modulation of mammary function, maintenance of bone trophism, regulation of hepatic metabolic genes, effects on the cardiovascular system and influence on numerous neuronal circuits. Estrogen physiology must therefore be understood as a multisystem transcriptional regulatory process, not as a phenomenon limited to reproductive function alone.

The differential distribution of ERα and ERβ adds a further level of selectivity. Some tissues are dominated by one of the two isoforms, while others express both in varying proportions, generating qualitatively different effects according to the receptor ratio and interaction with other endocrine signals. This receptor heterogeneity explains why estrogens can strongly stimulate some tissues, exert more modulatory effects in others and interact in complex ways with growth factors, cytokines and concomitant steroids.

The final result is a highly efficient endocrine control system in which estradiol acts as a regulator of gene expression programs. The effects develop over periods of hours or days and form the basis of the more stable changes induced by estrogen signaling at organ and system level.

Alongside classical nuclear action, estrogens can induce rapid responses through non genomic mechanisms. These pathways involve receptors associated with the plasma membrane or located in subcellular compartments that are capable of rapidly activating intracellular signaling cascades. Among the most relevant pathways are MAPK, PI3K/AKT and other circuits that modulate cellular function, survival, vascular tone and responses to growth signals.

The physiological importance of these mechanisms lies in their rapidity. While genomic action requires changes in gene expression, non genomic pathways allow estrogens to rapidly influence endothelial function, intracellular calcium dynamics, kinase activity and the sensitivity of other signaling systems. This enables the estrogen signal to operate over multiple time scales, ranging from long term transcriptional remodeling to acute modulation of cellular function.

Non genomic actions do not replace nuclear regulation, but complement it. In many tissues, the two levels of signaling converge and reinforce each other: a rapid response modifies the immediate cellular context, while the genomic response consolidates more durable adaptations. From an endocrinological perspective, this explains why estrogens can produce complex and integrated effects on the cardiovascular system, nervous system, metabolism and reproductive tissues.

The presence of rapid pathways also reinforces the concept that estrogen signaling depends not only on the amount of circulating hormone, but also on the ability of the target tissue to interpret the hormone through different molecular mechanisms. The final response therefore results from the convergence of hormone concentration, receptor distribution, coregulators and the functional state of the cell.

Estrogen physiology demonstrates that the endocrine signal is the result of a complex chain comprising ovarian steroidogenesis, cyclic secretion, plasma binding, peripheral metabolism and receptor interaction. Each step can be modulated by nutritional status, hepatic function, body composition, phase of the cycle, quality of the dominant follicle and concomitant endocrine conditions. Consequently, biochemical values alone do not describe the full intensity of the biological signal within tissues.

Estradiol is the principal marker of ovarian estrogen signaling, but its significance always depends on the temporal and physiological context in which it is measured. The same value may have different implications when observed during the early follicular phase, the preovulatory period or the luteal phase. Furthermore, tissue availability of the hormone does not automatically correspond to its serum concentration because binding proteins, local metabolism, interconversion with estrone and differences in receptor response all contribute.

In conclusion, the ovarian estrogen system is an endocrine model in which stability depends on transport and continuity of follicular production, while adaptability derives from cooperation between theca and granulosa cells, peripheral metabolism and tissue specific receptor regulation. Genomic action mediated by estrogen receptors explains the depth of effects on reproduction, bone, metabolism and the cardiovascular system, while non genomic pathways complete the picture with rapid and integrated responses. This view is essential for understanding ovarian physiology, the clinical significance of estradiol fluctuations and pathological conditions in which estrogen signaling is altered at central, gonadal or peripheral level.